Press release | Lund 2026-11-13

Coegin Pharma expands Nordic pharmacy presence – VEXIENNE® enters Danish pharmacies

Coegin Pharma AB ("Coegin" or the "Company") today announces a collaboration with Taastrup Apotek, a pharmacy operator with eight locations across Greater Copenhagen, to introduce VEXIENNE® Hair Active X™ in Denmark. The initial launch will cover three pharmacies before the end of 2026, marking another commercial milestone for Coegin's premium haircare brand.

The collaboration establishes VEXIENNE® in the Danish pharmacy channel and follows the recently announced agreement with MEDS in Sweden. Together, these initiatives strengthen Coegin's Nordic distribution footprint and advance its strategy to scale Follicopeptide® through selected pharmacy, retail and professional partners.

Hair Active X™ is a premium cosmetic gel serum powered by Follicopeptide®, Coegin's patented and clinically developed peptide technology for thinning hair. The initial Danish introduction is planned for November deliveries, with in-store availability expected before year-end.

"We are moving VEXIENNE® into another highly relevant sales channel and another Nordic market. Following our agreement with MEDS in Sweden, this is a further step in building a strong commercial platform for Follicopeptide®," says Jens Eriksson, CEO of Coegin Pharma. *"Pharmacies offer credibility, professional guidance and direct access to consumers seeking science-based solutions for thinning hair. Our ambition is to establish a scalable premium brand across Europe, and each new distribution partner brings us closer to that goal."*

"We see clear interest among pharmacy customers in credible solutions for thinning hair. Hair Active X™ is an exciting addition to our offering, combining science-based innovation with the professional advice our pharmacies provide," says Behzad Ghorbani, pharmacy owner, Taastrup Apotek.

The initial introduction will take place at three pharmacies in Copenhagen and Taastrup, with preparations under way for the planned launch before the end of 2026.

The agreement complements Coegin's existing private label partnerships and VEXIENNE® distribution model, supporting a broader and more diversified commercial footprint.

For further information, please contact:
Jens Eriksson, CEO, or Lars B. Rasmussen, CFO
Email: info@coeginpharma.com
Phone: 072-221 24 21

Coegin Pharma AB
c/o Medicon Village
223 81 Lund, Sweden
Registration number
559078-0465
coeginpharma.com
info@coeginpharma.com

About Taastrup Apotek
Led by pharmacist Behzad Ghorbani, Taastrup Apotek is part of a group of eight pharmacies across Greater and central Copenhagen: Taastrup Apotek, Hedehusene Apotek, Ishøj Lille Torv Apotek, Nytorv Apotek, Cityapoteket, Trianglen Central Apotek, Lyngbyvej Apotek and Strandboulevarden Apotek. The pharmacies combine accessible healthcare products with qualified, personal advice on medicines and health-related products.

About Coegin Pharma
Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. Its flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning, commercialized through selected partners and the Company's VEXIENNE® brand. Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation for skin tone enhancement.

With proprietary peptide technology, scalable in-house production and flexible commercial models, Coegin is building a differentiated platform for science-based cosmetic products.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The Company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit coeginpharma.com

Coegin Pharma AB
c/o Medicon Village
223 81 Lund, Sweden
Registration number
559078-0465
coeginpharma.com
info@coeginpharma.com